Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

Abundio Balgos,Suad Hannawi,Wen-Li Chen,Alaa Abuquta,Linda Safeldin,Aala Hassan,Ahmad Alamadi,Louie Tirador,Anjuli May Jaen,Ralph Elvi Villalobos,Chen Mo,Zi-Jing Yue,Ying Ma,Qing-Shuang Wang,Ren-Du Wen,Zheng Yao,Jia-Ping Yu,Wen-Rong Yao,Jian-Hui Zhang,Kun-Xue Hong,Yong Liu,Jing-Xin Li,Suad AI Hannawi
DOI: https://doi.org/10.1080/14760584.2024.2334423
2024-04-03
Expert Review of Vaccines
Abstract:Background Recombinant protein vaccines are vital for broad protection against SARS-CoV-2 variants. This study assessed ReCOV as a booster in two Phase 2 trials.
immunology
What problem does this paper attempt to address?